Analysts expect Voyager Therapeutics, Inc. (NASDAQ:VYGR) to report sales of $1.15 million for the current quarter, Zacks reports. Two analysts have made estimates for Voyager Therapeutics’ earnings, with the highest sales estimate coming in at $1.24 million and the lowest estimate coming in at $1.05 million. Voyager Therapeutics posted sales of $3.31 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 65.3%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 9th.

According to Zacks, analysts expect that Voyager Therapeutics will report full-year sales of $1.15 million for the current fiscal year, with estimates ranging from $4.70 million to $12.00 million. For the next financial year, analysts anticipate that the business will post sales of $16.83 million per share, with estimates ranging from $6.00 million to $32.20 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. The company had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $3.27 million.

Several research firms recently commented on VYGR. ValuEngine raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Chardan Capital reaffirmed a “hold” rating on shares of Voyager Therapeutics in a report on Sunday, September 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $33.00 target price on shares of Voyager Therapeutics in a report on Tuesday, June 27th. BidaskClub raised Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 13th. Finally, Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $24.83.

ILLEGAL ACTIVITY WARNING: “$1.15 Million in Sales Expected for Voyager Therapeutics, Inc. (VYGR) This Quarter” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/06/1-15-million-in-sales-expected-for-voyager-therapeutics-inc-vygr-this-quarter-2.html.

In other Voyager Therapeutics news, insider Bernard Ravina sold 5,490 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 27,450 shares of company stock worth $321,769 in the last quarter. 8.00% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. Hershey Trust Co. boosted its position in Voyager Therapeutics by 163.0% during the second quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after purchasing an additional 8,921 shares in the last quarter. Fiduciary Trust Co. boosted its position in Voyager Therapeutics by 19.1% during the first quarter. Fiduciary Trust Co. now owns 108,561 shares of the company’s stock worth $1,437,000 after purchasing an additional 17,386 shares in the last quarter. Wellington Management Group LLP boosted its position in Voyager Therapeutics by 17.4% during the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after purchasing an additional 19,450 shares in the last quarter. Teachers Advisors LLC boosted its position in Voyager Therapeutics by 9.8% during the fourth quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock worth $262,000 after purchasing an additional 1,847 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Voyager Therapeutics by 114.4% during the first quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock worth $1,107,000 after purchasing an additional 44,599 shares in the last quarter. Institutional investors own 40.70% of the company’s stock.

Voyager Therapeutics (NASDAQ:VYGR) opened at 20.43 on Friday. The stock’s market capitalization is $549.63 million. The stock’s 50 day moving average price is $14.42 and its 200-day moving average price is $11.06. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $22.95.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.